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Abstract. Paclitaxel (PTX) is a popular anticancer drug used in the treatment of
various types of cancers. PTX is metabolized in the human liver by cytochrome
P450 to two structural isomers, 3′-p-hydroxypaclitaxel (3p-OHP) and 6α-
hydroxypaclitaxel (6α-OHP). Analyzing PTX and its two metabolites, 3p-OHP and
6α-OHP, is crucial for understanding general pharmacokinetics, drug activity, and
drug resistance. In this study, electrospray ionization ion mobility mass spectrometry
(ESI-IM-MS) and collision induced dissociation (CID) are utilized for the identification
and characterization of PTX and its metabolites. Ion mobility distributions of 3p-OHP
and 6α-OHP indicate that hydroxylation of PTX at different sites yields distinct gas
phase structures. Addition of monovalent alkali metal and silver metal cations en-
hances the distinct dissociation patterns of these structural isomers. The differences observed in theCID patterns
of metalated PTX and its two metabolites are investigated further by evaluating their gas-phase structures.
Density functional theory calculations suggest that the observed structural changes and dissociation pathways
are the result of the interactions between the metal cation and the hydroxyl substituents in PTX metabolites.
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Introduction
Paclitaxel (PTX, Scheme 1) is a widely used drug in che-motherapy. PTX is prescribed alone or in combination
with other anticancer agents for several lung [1], breast [2],
ovarian [3], head, and neck cancers [4]. PTX binds to β-tubulin
and arrests the cell cycle in its mitotic phase, the cell cycle that
the parent cell divides into two daughter cells by separating
duplicated chromosomes and cell nucleus. Complexation of
PTX with β-tubulin enhances the polymerization of β-
tubulins and stabilizes the microtubules to inhibit treadmilling
dynamics, leading to inhibition of cancer cell division and cell
apoptosis [5, 6]. However, PTX treatment can fail because of
the various drug resistance mechanisms [6, 7]. The expression
of cytochrome P450 (CYP) is one of the factors contributing to
the resistance towards PTX [8–10]. The CYP family of en-
zymes plays a critical role in the phase I of drug metabolism
[11, 12]. Phase I of drug metabolism encompasses enzyme-
mediated modifications involving the addition or removal of
small chemical moieties to drugs, such as hydroxylation,
oxidation, deamination, and hydrolysis [13]. PTX is predomi-
nantly metabolized in the human liver by CYP to two structural
isomers, 3′-p-hydroxypaclitaxel (3p-OHP, Scheme 1) and 6α-
hydroxypaclitaxel (6α-OHP, Scheme 1) [14–16]. Therefore,
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monitoring metabolites of PTX resulting from the action of
CYP is critical to gain insights into chemotherapeutic drug
resistance [8, 9] and further pharmacokinetics studies [17,
18]. Several studies have analyzed PTX and its metabolites,
3p-OHP and 6α-OHP, in different samples, such as tissue
extract, serum, plasma, and urine, using tandem mass spec-
trometry interfaced with liquid chromatography (LC-MS/MS)
[19, 20]. These studies have shown that 3p-OHP and 6α-OHP
can be distinguished by the collision induced dissociation
(CID) patterns in their tandem mass spectra. Although
metabolite-specific fragments have been identified in previous
studies, their CID patterns are yet to be understood in relation
to their structural difference in the gas phase.
In the present study, using electrospray ionization ion mo-
bility mass spectrometry (ESI-IM-MS) and low-energy CID,
we have characterized PTX and its metabolites on the basis of
their gas-phase structural properties. IM-MS has been actively
utilized for various applications, including characterization of
the structures of small drug-like molecules [21, 22], peptides
[23, 24], proteins [25], and polymers [26]. Moreover, simulta-
neous characterization of molecular ions based on their gas-
phase conformations can provide valuable insights into their
potential structural isomers [27–30]. In an IM cell, ions collide
with neutral buffer gas and these collisions influence the trav-
eling time of the ions depending on their charge, size, and
shape. The traveling time of an ion can be converted into its
experimentally determined collision cross section (ΩD,exp).
Insights into the conformations are subsequently gained by
comparing the ΩD,exp to the theoretical ΩD (ΩD,theo) of
structural models generated by computation.
Introducing metal ions to organic molecules is beneficial for
ionizing organic compounds devoid of basic/acidic functional
groups. In addition, diverse interactions between different met-
al cations and ligand molecules allow unique structural rear-
rangements and dissociation pathways [31, 32]. Recent studies
demonstrated the effect of alkali metal and silver metal cations
to generate different CID patterns [33–35]. In case of alkali
metal cations, the ion sizes and binding properties influence the
complex structures and CID patterns [33, 36]. In addition,
silver metal cation shows specific fragmentation patterns,
which is considered to be related to the silver–π interaction
[34, 35, 37]. We therefore chose proton (H+), alkali metal (Li+,
Na+, and K+), and silver (Ag+) metal cations to investigate the
structural changes and CID patterns of PTX and its two me-
tabolites in the gas phase. Analyses of the results reveal that the
conformation and dissociation patterns of PTX and 3p-OHP
ions bear similarities. However, 6α-OHP ions show distinct
structures and CID patterns compared with those of PTX and
3p-OHP. CID of metalated PTX and its metabolites show
selective ester bond dissociations. Density functional theory
(DFT) calculation is performed to understand the observed
structural changes and dissociation pathways of PTX and its
metabolites.
Experimental
Materials
Paclitaxel (PTX), 3′-p-hydroxypaclitaxel (3p-OHP), and 6α-
hydroxypaclitaxel (6α-OHP) were purchased from BD Biosci-
ences (San Diego, CA, USA) and used without further purifi-
cation. Lithium chloride and sodium chloride were purchased
from Samchun Pure Chemical (Pyeongtaek, Korea). Potassium
chloride from Junsei Chemical (Tokyo, Japan) and silver ni-
trate from Tokyo Chemical Industry (Tokyo, Japan) were used.
HPLC-grade water, ethanol, (J. T. Baker, Phillipsburg, NJ,
USA) and formic acid (Sigma-Aldrich, St. Louis, MO, USA)
were used. Polyalanine was purchased from Sigma-Aldrich.
The final concentration of the analyte (PTX, 3p-OHP, and 6α-
OHP) was adjusted to 5 μM. Except for silver nitrate, all the
other metal salts were added to be equimolar with the analyte.
Silver nitrate concentration was selected to be 10-fold of pac-
litaxel and its metabolites to obtain observable signal of com-
plex. All sample solutions were prepared in 50/50 water/etha-
nol with 0.5% of formic acid by volume.
Electrospray Ionization Traveling Wave Ion
Mobility Mass Spectrometry (ESI-TWIM-MS)
IM-MS measurements were performed on a Synapt G2 HDMS
traveling wave ion mobility orthogonal acceleration time-of-
flight (Synapt G2 instrument, Waters, Milford, MA, USA) in
positive ion mode. Source temperature of 150°C, capillary
voltage of 3.5 kV, desolvation temperature of 200°C, and cone
voltage of 40 V were used as parameters for ESI. The helium
cell was set with a flow rate of 180 mL/min. Nitrogen drift gas
was introduced into the IM cell at a 60 mL/min of flow rate.
Optimized traveling wave height and velocity were 40 V and
600 m/s, respectively. For each sample, 120 spectra were
obtained and averaged. The arrival times of analyte ions were
extracted using MassLynx software (ver. 4.1, Waters, Milford,
MA, USA).Multiple peak fitting of IM spectra were performed
by Origin 9.0 software (OriginLab, Northampton, MA, USA)
with Gaussian function.
Scheme 1. Structure of PTX, 3p-OHP, and 6α-OHP
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Collision Induced Dissociation (CID)
Tandem MS experiments of cationized PTX, 3p-OHP and 6α-
OHP ions were performed on a Thermo Scientific Q-Exactive
hybrid quadrupole-Orbitrap mass spectrometer (Q-Orbitrap
instrument, Thermo Scientific, San Jose, CA, USA) in positive
ion mode. Samples were injected with a syringe pump at a flow
rate of 5 μL/min, and the electrospray voltage and capillary
temperature were set as 3.0 kV and 200°C, respectively.
Spectra of all samples were acquired over 200 scans and
averaged, and the peaks were analyzed using Thermo Xcalibur
2.1 software (Thermo Scientific). The 20% of the normalized
collision energy was applied to all analyte ions. Additional
tandem MS experiments were performed on the Synapt G2
HDMS instrument along with the IM separation in positive ion
mode at the trap (CID-IM-MS) and the transfer cell (IM-CID-
MS), which were placed before and after the IM cell, respec-
tively. Spectra of all samples were acquired over 200 scans and
averaged, and the peaks were analyzed using MassLynx soft-
ware (ver. 4.1, Waters, Milford, MA, USA). Forty eV of
collision energy was applied to all analyte ions, and the other
parameters were the same to the IM-MS experiments without
tandem MS.
Collision Cross Sections (ΩD)
The experimental collision cross sections (ΩD,exp) of cationized
PTX, 3p-OHP, or 6α-OHP were obtained using a calibration
method previously reported by Thalassinos et al. [38], based on
the published collision cross sections in helium drift gas (ΩHe).
Using polyalanine, a calibration curve was plotted by fitting
previously published ΩD values to the drift time of ions [39].
The arrival times of ions were corrected for mass-independent
and mass-dependent times to obtain effective drift times. Mass-
independent time corrections were made for the times required
to traverse the transfer and mobility cells, and the mass-
dependent time corrections were made for the TOF of each
ions. Then, the effective drift times were plotted against the
published ΩD values in power relationship to gain time-ΩD,exp
relationship. ΩD,theo values were calculated with the hard
sphere projection approximation model in the Sigma program
[40], which was successful in calculating ΩD,theo of molecules
with heteroatomic composition [41]. For lithium and silver,
whose parameters were absent in the Sigma and Mobcal pro-
gram, their van der Waals radii were assumed to be their gas-
phase hard sphere radii [42] in agreement with the hard sphere
descriptions of the Sigma program.
Density Functional Theory (DFT) Calculations
The gas-phase structures and energetics of cationized PTX, 3p-
OHP, and 6α-OHPwere determined by DFT calculations using
the Q-Chem 4.1 computational package (Q-Chem Inc., Pitts-
burgh, PA, USA). Initial PTX structure was extracted from
microtubule bound crystal structure (pdb id: 2HXF) and opti-
mized further at the B3LYP/6-31G(d) level of theory. For the
metabolites, hydrogen atoms at the 3p or 6α positions in the
optimized PTX structure were replaced with a hydroxyl group
to build the initial 3p-OHP or 6α-OHP structure, respectively.
Subsequently, the obtained 3p-OHP and 6α-OHP structures
were re-optimized at the B3LYP/6-31G(d) level. Over 20
potential cation binding sites were evaluated. The structures
of argentated complexes were optimized with B3LYP/
LANL2DZ-6-31G(d) [43], in which LANL2DZ ECPwas used
for silver and 6-31G(d) for all other atoms because the param-
eters for silver atom were not present in the B3LYP/6-31G(d)
basis set. Cationized fragments resulting from CID were opti-
mized at the B3LYP/6-31G(d) level. For the argentated frag-
ment ions, B3LYP/LANL2DZ-6-31G(d) level of calculation
was used for optimization. Zero-point energy was corrected for
all parent molecules and their CID products.
Results and Discussion
IM Distribution of PTX and Its Metabolites
with Various Cations
PTX and its two hydroxylated metabolites, 3p-OHP and 6α-
OHP, were evaluated by ESI-IM-MS (Synapt G2 HDMS in-
strument) with various monovalent cations (H+, Li+, Na+, K+,
and Ag+). Singly charged protonated or metalated ions were
observed in the mass spectra. The mass spectra obtained from
ESI-IM-MS were similar to those from the ultrahigh resolution
mass spectrometer (Q-Orbitrap instrument), and no dimers or
trimers were found, based on the isotope pattern in the both
instruments (Supplementary Figure S1).
The IM distributions of PTX and its hydroxylated metabo-
lites were examined to investigate the structural differences
induced by cationization. Figure 1a shows the IM spectra of
the PTX ions with various cations plotted against the ΩD,exp
values. In the gas phase, the protonated PTX ions ([PTX + H]+)
exist in two conformations, one with a ΩD of 204 Å
2 and the
other with 212 Å2. It is evident from the IM spectrum that the
compact conformer is more favored than the extended one.
Lithiated PTX ions ([PTX + Li]+) adopt two conformations
(ΩD ~ 204 and 211 Å
2), whereas sodiated PTX ions ([PTX +
Na]+) assume a single conformation (ΩD ~ 211Å
2). Potassiated
PTX ions ([PTX + K]+) predominantly exist as the conformer
with ΩD of 212 Å
2, with a tailing distribution in higher ΩD.
Argentated PTX ions ([PTX + Ag]+) possess a single confor-
mation (ΩD ~ 204 Å
2). In summary, PTX with alkali metal
cations predominantly prefer to exist in the conformers with
ΩD of 211–212 Å
2, whereas the argentated PTX ions assume a
relatively more compact conformer (ΩD ~ 204 Å
2).
The structural preferences for the cationized 3p-OHP are
similar to those of PTX. As seen in Figure 1b, the compact
conformer (ΩD ~ 209 Å
2) of [3p-OHP + H]+ is more abundant
than the extended conformer (ΩD ~ 217 Å
2). The alkali
metalated 3p-OHP ions dominantly form conformers with ΩD
of 216 Å2, and the argentated ion forms a conformer withΩD ~
208 Å2. By contrast, IM spectra of 6α-OHP ions are distinct
from those of PTX and 3p-OHP. Although two conformers are
also observed for the protonated 6α-OHP ions ([6α-OHP +H]+,
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Figure 1c), the larger conformer (ΩD ~ 213 Å
2) is preferred over
the smaller one (ΩD ~ 205 Å
2). The lithiated ions exist in three
conformers with ΩD of 209, 213, and 219 Å
2. The sodiated and
potassiated 6α-OHP ions ([6α-OHP + Na]+ and [6α-OHP + K]+)
have large structure with ΩD of 215 Å
2 and 217 Å2, respec-
tively. The argentated 6α-OHP ion ([6α-OHP + Ag]+) forms a
conformer with an intermediate size (ΩD ~ 211 Å
2).
Gas-Phase Structures of Cationized PTX
and Its Metabolites
To understand the observed conformational change of PTX
and its metabolites induced by attached cationic species, the
ΩD,theo of PTX and its metabolite ions were evaluated using the
DFT optimized structures. Figure 2 shows representative, en-
ergetically favored structures of PTX, 6α-OHP, and 3p-OHP
ions, wherein the ΩD,theo values show good agreement with
ΩD,exp. ΩD,exp are listed and compared with the ΩD,theo in
Table 1. See Supplementary Figure S2 for additional DFT
optimized structures and Supplementary Figures S3–S5 for
scatter plots ofΩD,theo versus potential energies. For protonated
PTX ions, theΩD,theo values of both energetically stable P1 and
P2 structures (Figure 2a and b) show good agreement with
ΩD,exp value of the larger conformer (~212 Å
2). In the P1
structure, the proton binds to the 2° amine group (N5), and
forms an intramolecular hydrogen bond with the adjacent
carbonyl group (O7). In the P2 structure, the protonated car-
bonyl group (O4) does not form an intramolecular hydrogen
bond with adjacent atoms. Nevertheless, the protonation of the
carbonyl oxygen O4 is favored because of the charge delocal-
ization through the adjacent phenyl (Ph1) and amine (N4)
groups (Supplementary Scheme S1). The ΩD,theo values calcu-
lated for A and B structures (Figure 2c and d) show good
agreement with ΩD,exp value of the small conformer
(~204 Å2). DFT-based calculations show that the A and B
structures are energetically stable in the case of [PTX + H]+.
In the A structure, protonation occurs at the carbonyl oxygen,
O18 (see Figure 2 for labels), whereas a hydrogen bond is
formed with a neighboring hydroxyl group, O15. For the B
structures, the hydrogen bonding network is formed between
the protonated O4 and O12.
Figure 1. IM spectra of cationized (a) PTX, (b) 3p-OHP, and (c) 6α-OHP. The data corresponding to H+, Li+, Na+, K+, and Ag+ binding
ions are displayed sequentially from top to bottom in each panel.ΩD,exp values and their standard deviations (Å
2) are displayed along
with fitted peaks
Figure 2. Representative structures from DFT calculations.
Potential interactions between electron donors, such as oxygen
atoms and phenyl groups, and the nearby cations are indicated
with dashed lines; representative (a) P1 and (b) P2 structures
from [PTX+H (yellow sphere)]+, (c) A, (d) B structure from [PTX +
Li (purple sphere)]+, (e) C structure from [PTX + Ag (orange
sphere)]+, and (f) D structure from [6α-OHP + Li]+. The rest of
the structures are shown in Supplementary Figure S2
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Two energetically favored structures are typically observed
for alkali metalated PTX ions (Figure 2c and d). In the A
structure (Figure 2c), the three oxygen atoms (O15, O16, and
O18) interact with the alkali metal cations. In the B structure
(Figure 2d), the metal cation is interacting with the O4, O8, and
O12 atoms. Our theoretical analysis indicates that a A or B
structure can be the dominating conformer for all alkali
metalated PTX ions, except for [PTX + K]+. In case of [PTX
+ K]+, the ΩD,theo of B structure is in more close agreement
with theΩD,exp of the dominating structure, whereas theΩD,theo
of A structure agrees with that of the tailing conformer.
The most compact metalated structure determined on the
basis of our DFT calculations is the C structure (Figure 2e),
wherein the metal cation interacts with the Ph3, O4, and O9
atoms. C structure is energetically favored in case of [PTX +
Ag]+. In addition, ΩD,theo of C structure is close to ΩD,exp,
which explains the compactness of [PTX + Ag]+ in the IM
distribution. Moreover, the C structure indicates that silver
metal cation has a distinguishable cation–π interaction com-
pared with alkali metal cations. The silver metal cation is
positioned at the periphery of the phenyl ring Ph3. However,
the silver metal cation positioned at the periphery of the ring
retains comparably strong interaction to that of the silver–π
interaction at the center of the ring [44]. Furthermore, X-ray
crystal structures of related argentated ligands reveal that silver
metal cations are bound at the periphery of the aromatic ring
[45], as observed in the C structure.
IM spectra of cationized 3p-OHP show similar trends as
those observed with PTX (Figure 1a and b). While cations tend
to interact simultaneously with multiple electron-rich function-
al groups to maximize the binding energy, the long distance
between the potential cation binding sites and the hydroxyl
group at the 3p position precludes potential ion–dipole inter-
actions. As a consequence, DFT optimized structures of
cationized 3p-OHP are generally consistent with those
observed in the case of PTX while retaining marginally higher
ΩD,theo values owing to the hydroxyl group at the 3p position
(Supplementary Table S1).
Cationized 6α-OHP have specific, energetically stable
conformers classified as D structures (Figure 2f). In the
protonated ions, the O4 and O6α atoms are involved in
hydrogen bonding. In case of the metalated ions, the O4,
O12, and O6α atoms interact with the attached metal cation.
D structure shows relatively small ΩD,theo values for
cationized 6α-OHP. The stability and compactness of D
structure provides further support to the observation that
the structures of [6α-OHP+ Li]+ and [6α-OHP + Na]+ are
relatively more compact when compared with those from
PTX and 3p-OHP (Figure 1c). ΩD,theo value of D structure
is also consistent with the ΩD,exp in the [6α-OHP + Ag]
+.
Collision Induced Dissociations of PTX
and Its Metabolites
PTX and its metabolites were investigated further using colli-
sion induced dissociation (CID) in an ultrahigh resolution mass
spectrometer (Q-Orbitrap instrument). Figure 3 shows CID
mass spectra of cationized PTX, 3p-OHP, and 6α-OHP. The
proposed structures of CID fragments are shown in Scheme 2
and listed in Supplementary Tables S2−S4.
The CID of [PTX + H]+ yields over 40 fragments (see the
top panel, Figure 3a, and Supplementary Table S2). The frag-
ment termed L (m/z 285), resulting from the dissociation of the
ester bond O8−C 19 (see Figure 2 for the labeling of atoms), is
the most abundant fragment (Scheme 2). The L subfragment
product resulting from the loss of formic acid (–46 Da) is also
observed at m/z 239 (L1). The loss of 46 Da can also be
explained by the consecutive loss of H2O and CO [46]. The
expected R fragment (m/z 568), resulting from the loss of
neutral L fragment from PTX, is not observed in the CID mass
spectra. However, R subfragment products from the dissocia-
tion of ester bonds as acetic acids (−60 Da, AA) and/or as
Table 1. Comparison of Experimental and TheoreticalΩD Values (Å
2). Standard Deviation (σ) of Fitted Gaussian Curve is Noted withΩD.exp. Standard Deviation is
also Noted with ΩD,theo. Corresponding Structures are Listed with Bold Characters. See Supplementary Figure S2 for the Descriptions of E Structure
PTX 3p-OHP 6α-OHP
ΩD,exp ΩD,theo ΩD,exp ΩD,theo ΩD,exp ΩD,theo
H+ Compact 204 ± 3 207 ± 2 (A)
207 ± 1 (B)
209 ± 2 211 ± 1 (A)
210 ± 2 (B)
205 ± 3 208 ± 1 (A)
204 ± 1 (D)
Extended 212 ± 4 212 ± 1 (P1)
211 ± 1 (P2)
217 ± 3 215 ± 2 (P1)
217 ± 1 (P2)
213 ± 3 213 ± 1 (P1)
212 ± 1 (P2)
Li+ Fronting 204 ± 2 206 ± 1 (E) 209 ± 3 209 ± 1 (E) 209 ± 3 208 ± 2 (D)
Dominating 211 ± 3 210 ± 2 (A)
212 ± 2 (B)
216 ± 3 214 ± 2 (A)
215 ± 1 (B)
213 ± 2 211 ± 1 (A)
213 ± 1 (B)
Tailing - - - - 219 ± 3 -
Na+ Fronting - - - - 210 ± 2 208 ± 2 (D)
Dominating 211 ± 3 213 ± 2 (A)
212 ± 1 (B)
216 ± 3 216 ± 2 (A)
214 ± 1 (B)
215 ± 3 213 ± 1 (A)
215 ± 2 (B)
K+ Dominating 212 ± 3 212 ± 1 (B)
211 ± 1 (E)
216 ± 3 215 ± 1 (B) 217 ± 3 219 ± 1 (A)
214 ± 2 (D)
Tailing 218 ± 4 219 ± 2 (A) 222 ± 5 222 ± 1 (A) - -
Ag+ Dominating 204 ± 3 204 ± 2 (C) 208 ± 3 207 ± 2 (C) 211 ± 3 210 ± 1 (D)
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benzoic acid (–122 Da, BA) are observed at m/z 508 (R1), 448
(R2), 386 (R3), and 326 (R4) (Scheme 2). Unidentified frag-
ments were observed over the m/z range between 150 and 350.
In the CID mass spectra of the metalated PTX ions, ester bond
dissociation occurs selectively. L, R, and R1 fragments are
observed as dominating fragments in the CID mass spectra of
all alkali metalated PTX ions (Figure 3a). These fragments
were observed in previous reports that studied PTX, also with
similar trends in the abundances [19, 20]. The CID mass
spectra of [PTX + Ag]+ also displays fragments resulting from
the cleavage of ester bonds (R, R1, R2, R3, R4, and L). The
phenyl group containing small fragments, L2 and L4, with m/z
121 and 120, respectively, is particularly observed. The pres-
ence of L2 and L4 is consistent with the predicted strong
silver–π interaction in [PTX +Ag]+. Considering that silver–π
interaction is sustained during the low energy CID [37, 47],
Figure 3. Tandem mass spectra of (a) PTX, (b) 3p-OHP, and (c) 6α-OHP ions. See Scheme 2 for the fragment structures and
Supplementary Tables S2–S4 for the relative abundances with observedm/z and exact mass. L(3p) is L fragment of 3p-OHP, which
is identical to L fragment except for hydroxyl group at the para position of phenyl group, Ph2. R(6α) is a R fragment that has extra
hydroxyl group at the 6α position
Scheme 2. Proposed structures and molecular weights of L and R fragments and their subfragments, L1–L4 and R1–R4,
respectively
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silver–π interaction may play a potential role in the fragmenta-
tion pathway as observed with L2 and L4.
The dissociation patterns observed in the CID mass spectra of
alkali metalated 3p-OHP ions show almost identical patterns
compared with those of alkali metalated PTX ions (Figure 3b,
Supplementary Table S3). On the other hand, the CID mass
spectra of cationized 6α-OHP display patterns that are different
from those of PTX and 3p-OHP (Figure 3c, Supplementary
Table S4). Fewer fragments are observed in the m/z range 150 to
350 for protonated 6α-OHP ions. The relative abundances of the R
and R1 fragments are higher for alkali metalated 6α-OHP ions.
Series of IM-CID-MS (Supplementary Figure S6) experi-
ments were also performed at the transfer of the Synapt G2
HDMS instrument, and the results have shown good agreement
with those acquired from the Q-Orbitrap instrument (Figure 3).
The calculated ratios between the sum of L fragment and its
subfragments over those of R fragments are similar to those
obtained from the Q-Orbitrap instrument (L/R fragment ratio,
Supplementary Figures S7 and S8), except for the lithiated ions.
Multiple collisions during the CID process at the transfer cell may
have caused the loss of L fragments for the lithiated ions. Nev-
ertheless, the similarities between the two series of data indicate
the generality of our experimental observations. However, rela-
tive abundances of the L fragments are notably reduced in the
series of CID-IM-MS experiments (Supplementary Figures S9
and S10). The high energy of ions attained from acceleration at
the trap cell may have caused the escape of the L fragments from
the confinement of the TW ion guide, during the IM separation.
The ester bond dissociation in the gas phase occurs via
thermal ester elimination reaction (Scheme 3) [48, 49]. The
ester bond is cleaved when the carbonyl oxygen of the ester
group donates electrons to β-hydrogen and the ether oxygen
withdraws electrons from the Cα [49]. Also, ester bond disso-
ciation can occur by ether oxygens, which donate electrons to
Cβ, and carbonyl oxygens, which withdraw electrons from β-
hydrogen (Scheme 3) [36]. It is known that a charge
withdrawing/donating group attached to Cα or Cβ affects the
rate of ester elimination reaction [49]. Thus, we suggest that
ion–dipole interaction between cation and either of the ester
oxygen atoms O7 or O8 stabilizes the L/R fragmentation
reaction intermediate by enhancing electron withdrawing pow-
er of an ester oxygen atom.
The B structure on Figure 2d, which corresponds to the
dominant conformers of the overall alkali metalated PTX ions,
displays the metal cations interacting with the O4, O8, and O12
atoms. The alkali metal cations, bound to the ester group oxygen
(O8), facilitate the charge-induced fragmentation (Scheme 4a)
[36]. Interactions between alkali metal cations and the O4 and
O8 result in a high abundance of L fragment from the CID of the
alkali metalated PTX ions (Figure 3a, Supplementary
Figure S7). Interaction of alkali metal cation with the carbonyl
oxygen O12 is responsible for the formation of R fragment. In
addition, abundant R1 might be attributed to the fragmentation
of AA, by stabilizing the intermediate in the dissociation reac-
tion of the acetate ester, through the ion–dipole interaction
between alkali metal cations and the carbonyl oxygen O12. This
explains the presence of R1 fragment along with R fragment in
CID mass spectra of all alkali metalated ions in Figure 3a.
Since the hydroxyl group at the 3p position is not directly
involved in the interaction with metal cations (Supplementary
Table S1), the CID mass spectra of alkali metalated ions of 3p-
OHP ions show almost identical dissociation patterns to those
of PTX. In contrast to 3p-OHP, IMmeasurements and the DFT
calculations indicate that the metal cation interacts with the O4,
O12, and O6α atoms in 6α-OHP (see D structure, Figure 2f).
Although the metal cation does not interact with the ester group
(O7 and O8), the ester bond is selectively dissociated, as
Scheme 3. Simplified scheme for the ester bond dissociation
mechanism
Scheme 4. Simplified scheme for (a) charge-induced ester
bond dissociation reaction (CIF) initiated from alkali metal cat-
ions in B structure. Two L type oxygen atoms (O4 and O8) and
one R type oxygen atom (O12) interact with the metal cation in
PTX and 3p-OHP. (b) Charge remote fragmentation (CRF) via D
structure shows twoR type oxygen atoms (O12, O6α) and one L
type oxygen atom (O4) are binding with metal cation in 6α-OHP
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indicated by the CID mass spectra of the alkali metalated 6α-
OHP ions (Figure 3c). We infer that these dissociations occur
via charge-remote fragmentation, a dissociation process that is
independent of the charge state and charge binding site
(Scheme 4b) [50]. As thermal ester elimination reaction occurs
without cations near ester oxygen atoms in the gas phase, the
previously reportedmechanism [49] for this reaction is likely to
be the mechanism of the charge-remote ester bond dissociation.
Interaction of the metal cation with the O12 and O6α increases
the probability of localizing the charge-carrying metal cation to
R fragment after ester bond dissociation by CID. Yet, L frag-
ment is still abundant from the CID mass spectra of the alkali
metalated 6α-OHP ions because of the charge delocalization at
benzamide O4 (Supplementary Scheme S1).
Again, DFT calculations were performed to address the ener-
getic comparisons between the metalation of L and R fragments.
Since the addition of cations introduces additional vibrational
modes, transition state structures with the cations can only be
calculated with reasonable computational cost when the molecule
is small and its potential cation binding sites are not spread over
the molecule [34, 37]. PTX is too large (854 Da), and its potential
cation binding sites are spread over the molecule. For this reason,
we calculated the final structure and the energies of L and R
fragment ions with the metal cations. Calculated energetics for
the ester bond dissociation is shown in Figure 4 with DFT
optimized geometries. As seen in Figure 4a, the overall L/R
dissociation reaction is endothermic by ~60–80 kJ/mol. The bind-
ing of the metal cation to the O4 and O8 atoms in the L fragments
of PTX, 3p-OHP, and 6α-OHP is energetically most favored to all
metal cations investigated in this study (L4,8 structure, Figure 4b).
The second most favored binding sites are Ph2 and O4 (L2,4
structure, Figure 4c). The energy gap between the two structures
is ~20–50 kJ/mol for alkali metalated L fragment ions (Supple-
mentary Table S5). However, in the case of the argentated mol-
ecules, the difference in the energies of L4,8 and L2,4 structures is
negligible [B3LYP/LANL2DZ-6-31G(d), Supplementary
Table S5], indicating that the strong silver–π interaction can
influence fragmentation pathways. Interaction of the metal cations
with the O15, O16, and O18 (R15,16,18 structure, Figure 4d) in the
R fragments is favored over the interactionswith theO12 andO14
(R12,14 structure Figure 4e) by ~35–70 kJ/mol (Supplementary
Table S6) for the all metalated PTX 3p-OHP, and 6α-OHP ions.
The energetic comparisons reveal that metalation of the
R15,16,18 fragment is favored energetically over the metalation of
the L4,8 fragment by ~20–40 kJ/mol (Supplementary Table S7).
However, the sum of L fragment and its subfragments is higher
than that of R type products for alkali metalated PTX and 3p-OHP
ions (Figure 3a and b, Supplementary Figure S7). Only in the CID
mass spectra of alkali metalated 6α-OHP ions, the sum of L
fragments to that of R fragments are comparable (Figure 3c,
Supplementary Figure S7). Metal cations prefer to interact with
the O12 atom in the B and D structures (Figure 2), which are
energetically favored in PTX and its metabolites before the CID.
Thus, it is inferred that metal cations are kinetically trapped by the
O12 atom of the R fragment, along with the O4 and O8 atoms in
the L fragment, during the ester bond dissociation via charge-
induced fragmentation for the PTX and 3p-OHP. The dissociation
of ester bonds from metalated 6α-OHP seem to occur via charge-
remote fragmentation in the D structure where metal cation is
interacting with two oxygen atoms (O12 and O6α) prior to the
CID. As a result, metalated L fragments are observed with high
relative abundances during CID of PTX and 3p-OHP ions for the
metal interaction with the O4 and O8 atoms in B structure
(Figure 3a and 7b, Supplementary Figure S7). The comparable
Figure 4. (a) Simplified reaction coordinate diagram of L/R fragmentation. The reaction is endothermic by 60–80 kJ/mol. Further
energetic details of the L/R fragment structures are listed in Supplementary Tables S6–S8. The dotted segment of the curve
represents the undetermined transition state and activation energy. Nevertheless, calculated trends in energetic difference between
[L4,8 +M]+ + [R] and [R12,14 +M]+ + [L] support observed L/R fragment ratios fromPTX and itsmetabolites. (b) 2D and 3D structures
of L4,8 fragment, which is the most energetically favored structure. (c) 2D and 3D structures of second most favored L fragment
structure, L2,4. 2D and 3D structures of (d) R15, 16, 18 fragments and (e) R12, 14 fragments are also displayed
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relative abundances of the L fragments and R fragments from the
CID mass spectra of metalated 6α-OHP can be explained by the
metal cation interaction with O12 and O6α atoms in D structure
(Scheme 4b). Further support is provided by DFT calculations,
which shows that the smaller energy differences between the
metalation of L4,8 and R12,14 fragments in 6α-OHP ions compared
with those of PTX and 3p-OHP ions (Supplementary Table S8).
Conclusion
Gas-phase structures and dissociation patterns of cationized
PTX and its two major CYP metabolites, 3p-OHP and 6α-
OHP, were investigated using ESI-IM-MS, CID, and DFT
calculations. Results from the IM-MS and DFT studies indicate
that the hydroxyl substituent position significantly influences
interactions between the metabolites and monovalent cations,
leading to distinct gas-phase conformations for 3p-OHP and
6α-OHP. All metal cations investigated in this study selectively
dissociate the ester bonds of PTX and its metabolites by CID.
The presence of the hydroxyl group at the 6α positions plays an
essential role in the interaction of 6α-OHP with cations,
resulting in conformations and dissociation patterns distinct
from those exhibited by PTX and 3p-OHP.
In this study, we demonstrated the utility of IM-MS and
theoretical calculations on understanding the structures and the
fragment formation process of PTX and its metabolites. IM-
MS is a powerful tool that offers valuable insights into the
structural dynamics of isomeric drug metabolites in the gas
phase. Utilizing IM-MS analysis, a correlation between the
CID pathways and gas-phase structures was established for
PTX and its two hydroxylated isomers, especially in relation
to metalation.
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